Targeted Therapy for Melanomas Without BRAF V600 Mutation.

Abstract excerpt

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for patients with metastatic melanoma; however, there remains an unmet clinical need for alternative treatment options for those patients who are either intolerant or refractory to immunotherapy. Here we review the role and clinical efficacy of targeted therapies for BRAFV600 wild-type melanoma. RECENT FINDINGS:...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Checkpoint Inhibitors
• Share to Immunotherapy
• Share to Melanoma